John Murphy is the President and CEO of the Association of Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need. John is at the forefront of AAM’s efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members.
He previously served as Chief Policy Officer and Senior Healthcare Counsel at the Biotechnology Innovation Organization (BIO), where he led domestic and international policy initiatives and directed the legal affairs of BIO’s healthcare division.
John holds degrees from Villanova University and the Catholic University Columbus School of Law. His career also includes experience in healthcare regulatory and enforcement matters at Hogan Lovells, LLP, as well as serving as Assistant General Counsel for the Pharmaceutical Research and Manufacturers of America (PhRMA).